{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T01:30:26Z","timestamp":1770514226737,"version":"3.49.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003105","name":"Universidade Federal de Uberl\u00e2ndia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003105","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017425","name":"Pr\u00f3-Reitoria de Pesquisa e P\u00f3s-Gradua\u00e7\u00e3o, Universidade Federal do Par\u00e1","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017425","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon: X"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.toxcx.2021.100083","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T22:47:55Z","timestamp":1630536475000},"page":"100083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Analgesic potential of different available commercial brands of botulinum neurotoxin-A in formalin-induced orofacial pain in mice"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2361-1157","authenticated-orcid":false,"given":"Thays Crosara","family":"Abrah\u00e3o Cunha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1956-0791","authenticated-orcid":false,"given":"Ana Claudia","family":"Gontijo Couto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5664-2526","authenticated-orcid":false,"given":"Rafael Tardin","family":"Rosa Ferraz Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graziella","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassia Regina","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxcx.2021.100083_bib1","series-title":"Botox [package Insert]","year":"2011"},{"key":"10.1016\/j.toxcx.2021.100083_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1526-4610.43.7s.3.x","article-title":"Evidence for antinociceptive activity of botulinum toxin type A in pain management","volume":"43","author":"Aoki","year":"2003","journal-title":"Headache J. Head Face Pain"},{"key":"10.1016\/j.toxcx.2021.100083_bib3","first-page":"10","volume":"vol. 13","author":"Aoki","year":"2006"},{"key":"10.1016\/j.toxcx.2021.100083_bib4","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1471-4159.1988.tb02482.x","article-title":"Characterization of the inhibitory action of botulinum neurotoxin type A on the release of several transmitters from rat cerebrocortical synaptosomes","volume":"50","author":"Ashton","year":"1988","journal-title":"J. Neurochem."},{"key":"10.1016\/j.toxcx.2021.100083_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.adaj.2016.09.013","article-title":"Effectiveness of botulinum toxin type A for the treatment of chronic masticatory myofascial pain: a case series","volume":"148","author":"Baker","year":"2017","journal-title":"J. Am. Dent. Assoc."},{"key":"10.1016\/j.toxcx.2021.100083_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/WNF.0b013e3181c46f61","article-title":"Prospective, randomized, double-blind study, comparing botulinum toxins type a botox and prosigne for blepharospasm and hemifacial spasm treatment","volume":"33","author":"Barasnevicius Quagliato","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.toxcx.2021.100083_bib7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/BF00505657","article-title":"Tetanus toxin and botulinum A toxin inhibit release and uptake of various transmitters, as studied with particulate preparations from rat brain and spinal cord","volume":"316","author":"Bigalke","year":"1981","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.toxcx.2021.100083_bib8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/mds.870040401","article-title":"Adductor laryngeal dystonia (spastic dysphonia): treatment with local injections of botulinum toxin (Botox)","volume":"4","author":"Brin","year":"1989","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxcx.2021.100083_bib9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2147\/BTT.S65603","article-title":"Botulinum toxin type A products are not interchangeable: a review of the evidence","volume":"8","author":"Brin","year":"2014","journal-title":"Biol. Targets & Ther."},{"key":"10.1016\/j.toxcx.2021.100083_bib10","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1067\/mjd.2002.121356","article-title":"A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines","volume":"46","author":"Carruthers","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.toxcx.2021.100083_bib11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2334\/josnusd.16-0614","article-title":"Efficacy of botulinum toxin therapy in treatment of myofascial pain","volume":"59","author":"Chaurand","year":"2017","journal-title":"J. Oral Sci."},{"key":"10.1016\/j.toxcx.2021.100083_bib12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.abb.2012.05.016","article-title":"Inhibitory effect of botulinum toxin type A on the NANC system in rat respiratory models of neurogenic inflammation","volume":"524","author":"Chien","year":"2012","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.toxcx.2021.100083_bib13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0304-3959(94)00273-H","article-title":"The orofacial formalin test in rats: effects of different formalin concentrations","volume":"62","author":"Clavelou","year":"1995","journal-title":"Pain"},{"key":"10.1016\/j.toxcx.2021.100083_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0006-8993(90)91835-5","article-title":"Central nervous system plasticity in the tonic pain response to subcutaneous formalin injection","volume":"535","author":"Coderre","year":"1990","journal-title":"Brain Res."},{"key":"10.1016\/j.toxcx.2021.100083_bib15","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/ejp.513","article-title":"Intrathecal administration of botulinum toxin type A improves urinary bladder function and reduces pain in rats with cystitis","volume":"18","author":"Coelho","year":"2014","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.toxcx.2021.100083_bib16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pain.2003.10.008","article-title":"Subcutaneous administration of botulinum toxin a reduces formalin-induced pain","volume":"107","author":"Cui","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.toxcx.2021.100083_bib17","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1155\/2014\/410415","article-title":"Blockade of glutamate release by botulinum neurotoxin type A in humans: a dermal microdialysis study","volume":"19","author":"Da Silva","year":"2014","journal-title":"Pain Res. Manag."},{"key":"10.1016\/j.toxcx.2021.100083_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0304-3940(87)90242-4","article-title":"Peripheral origins and central modulation of subcutaneous formalin-induced activity of rat dorsal horn neurones","volume":"83","author":"Dickenson","year":"1987","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.toxcx.2021.100083_bib19","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache"},{"key":"10.1016\/j.toxcx.2021.100083_bib20","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1080\/09638280701568296","article-title":"Pharmacology of therapeutic botulinum toxin preparations","volume":"29","author":"Dressler","year":"2007","journal-title":"Disabil. Rehabil."},{"key":"10.1016\/j.toxcx.2021.100083_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00702-011-0719-1","article-title":"Measuring the potency labelling of onabotulinumtoxinA (Botox\u00ae) and incobotulinumtoxinA (Xeomin\u00ae) in an LD50 assay","volume":"119","author":"Dressler","year":"2012","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.toxcx.2021.100083_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00702-013-1076-z","article-title":"Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox\u00ae) and incobotulinumtoxinA (Xeomin\u00ae)","volume":"121","author":"Dressler","year":"2014","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.toxcx.2021.100083_bib23","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00702-018-1897-x","article-title":"Comparing incobotulinumtoxinA (Xeomin\u00ae) and onabotulinumtoxinA (Botox\u00ae): identical potency labelling in the hemidiaphragm assay","volume":"125","author":"Dressler","year":"2018","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.toxcx.2021.100083_bib24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0304-3959(77)90130-0","article-title":"The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats","volume":"4","author":"Dubuisson","year":"1977","journal-title":"Pain"},{"key":"10.1016\/j.toxcx.2021.100083_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/toxins10120535","article-title":"AbobotulinumtoxinA (Dysport\u00ae), OnabotulinumtoxinA (Botox\u00ae), and IncobotulinumtoxinA (Xeomin\u00ae) neurotoxin content and potential implications for duration of response in patient","volume":"10","author":"Field","year":"2018","journal-title":"Toxins"},{"key":"10.1016\/j.toxcx.2021.100083_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/11584780-000000000-00000","article-title":"Content of botulinum neurotoxin in botox\u00aevistabel \u00ae, dysport\u00aeazzalure\u00ae, and xeomin\u00aebocouture","volume":"10","author":"Frevert","year":"2010","journal-title":"Drugs R"},{"key":"10.1016\/j.toxcx.2021.100083_bib27","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/CCID.S160723","article-title":"Comparison of botulinum neurotoxin type a formulations in asia","volume":"11","author":"Frevert","year":"2018","journal-title":"Clin. Cosmet. Invest. Dermatol."},{"key":"10.1016\/j.toxcx.2021.100083_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0079-6123(00)26003-2","article-title":"The prefrontal cortex and the integration of sensory, limbic and autonomic information","volume":"126","author":"Groenewegen","year":"2000","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.toxcx.2021.100083_bib29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e3181692735","article-title":"Potencyevaluation of a formulated drug product containing 150-kd botulinum neurotoxin type a","volume":"32","author":"Hunt","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.toxcx.2021.100083_bib30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.neulet.2016.02.020","article-title":"Effects of botulinum toxin type A facial injection on monoamines and their metabolites in sensory, limbic and motor brain regions in rats","volume":"617","author":"Ibragi\u0107","year":"2016","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.toxcx.2021.100083_bib31","series-title":"Dysport [package Insert]. Paris","author":"IpsenBiopharm","year":"2009"},{"key":"10.1016\/j.toxcx.2021.100083_bib32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.toxicon.2017.09.003","article-title":"An update on new and unique uses of botulinum toxin in movement disorders","volume":"147","author":"Jankovic","year":"2018","journal-title":"Toxicon"},{"key":"10.1016\/j.toxcx.2021.100083_bib33","first-page":"1","article-title":"Potency and persistence of reconstituted botulinum neurotoxin type A: mouse IP LD50 assay","author":"Jeong","year":"2019","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.toxcx.2021.100083_bib34","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jpain.2010.07.002","article-title":"The prevalence of chronic pain in United States adults: results of an internet-based survey","volume":"11","author":"Johannes","year":"2010","journal-title":"J. Pain"},{"key":"10.1016\/j.toxcx.2021.100083_bib35","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s40261-018-0668-7","article-title":"Botulinum toxin type A overdoses: analysis of the FDA adverse event reporting system database","volume":"38","author":"Kazerooni","year":"2018","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.toxcx.2021.100083_bib36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1213\/ANE.0b013e3181ffa1d7","article-title":"Intrathecal administration of botulinum neurotoxin type a attenuates formalin-induced nociceptive responses in mice","volume":"112","author":"Lee","year":"2011","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.toxcx.2021.100083_bib37","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jpain.2006.04.010","article-title":"The orofacial formalin test in the mouse: a behavioral model for studying physiology and modulation of trigeminal nociception","volume":"7","author":"Luccarini","year":"2006","journal-title":"J. Pain"},{"key":"10.1016\/j.toxcx.2021.100083_bib38","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.brainres.2006.01.117","article-title":"Botulinum neurotoxins and formalin-induced pain: central vs. peripheral effects in mice","volume":"1082","author":"Luvisetto","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.toxcx.2021.100083_bib39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1034\/j.1600-0528.2002.300108.x","article-title":"Oro-facial pain in the community\u00a0: prevalence and associated impact","volume":"30","author":"Macfarlane","year":"2002","journal-title":"Community Dent. Oral Epidemiol."},{"key":"10.1016\/j.toxcx.2021.100083_bib40","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.biopha.2017.11.001","article-title":"Orofacial antinociceptive effect of Mimosa tenuiflora (Willd.)","volume":"97","author":"Magalh\u00e3es","year":"2018","journal-title":"Poiret. Biomed. Pharmacother."},{"key":"10.1016\/j.toxcx.2021.100083_bib41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00702-012-0846-3","article-title":"Comparison of analgesic effects of single versus repeated injection of botulinum toxin in orofacial formalin test in rats","volume":"120","author":"Matak","year":"2013","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.toxcx.2021.100083_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/toxins11080459","article-title":"Mechanisms of botulinum toxin type A action on pain","volume":"11","author":"Matak","year":"2019","journal-title":"Toxins"},{"key":"10.1016\/j.toxcx.2021.100083_bib43","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/0041-0101(96)00070-0","article-title":"Therapeutic botulinum type a toxin: factors affecting potency","volume":"34","author":"McLellan","year":"1996","journal-title":"Toxicon"},{"key":"10.1016\/j.toxcx.2021.100083_bib44","doi-asserted-by":"crossref","first-page":"21338","DOI":"10.1016\/S0021-9258(19)36614-1","article-title":"Tetanus toxin and botulinum toxins type A and B inhibit glutamate, \u03b3- aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes: clues to the locus of action","volume":"267","author":"McMahon","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.toxcx.2021.100083_bib45","series-title":"Xeomin [package Insert]. Frankfurt, Germany","author":"MerzPharmaceuticals","year":"2010"},{"key":"10.1016\/j.toxcx.2021.100083_bib46","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbrc.2009.01.037","article-title":"The N-terminal half of the receptor domain of botulinum neurotoxin A binds to microdomains of the plasma membrane","volume":"380","author":"Muraro","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.toxcx.2021.100083_bib47","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jnnp.64.1.6","article-title":"A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport\u00ae and Botox\u00ae in the treatment of cervical dystonia","volume":"64","author":"Odergren","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.toxcx.2021.100083_bib48","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1504\/TBJ.2008.018956","article-title":"Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use","volume":"1","author":"Panjwani","year":"2008","journal-title":"Botulinum J."},{"key":"10.1016\/j.toxcx.2021.100083_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11916-016-0545-0","article-title":"Botulinum Toxin\u00a0: pharmacology and therapeutic roles in pain states","volume":"20","author":"Patil","year":"2016","journal-title":"Curr. Pain Headache Rep."},{"key":"10.1016\/j.toxcx.2021.100083_bib50","series-title":"Clinical Applications of Botulinum Neurotoxin, Botulinum Toxin as a Clinical Product: Manufacture and Pharmacology","author":"Pickett","year":"2014"},{"key":"10.1016\/j.toxcx.2021.100083_bib51","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.febslet.2010.11.045","article-title":"Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1","volume":"585","author":"Pier","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.toxcx.2021.100083_bib52","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum neurotoxins: biology, pharmacology, and toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.toxcx.2021.100083_bib53","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0006-2952(00)00260-4","article-title":"Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms","volume":"59","author":"Purkiss","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.toxcx.2021.100083_bib54","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.neubiorev.2003.12.003","article-title":"The orofacial formalin test","volume":"28","author":"Raboisson","year":"2004","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.toxcx.2021.100083_bib55","doi-asserted-by":"crossref","DOI":"10.1007\/s11940-018-0488-3","article-title":"Botulinum toxin treatment of movement disorders","volume":"20","author":"Safarpour","year":"2018","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.toxcx.2021.100083_bib56","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/00002508-200211001-00013","article-title":"Treatment of temporomandibular disorders with botulinum toxin","volume":"18","author":"Schwartz","year":"2002","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.toxcx.2021.100083_bib57","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1526-4637.2008.00526.x","article-title":"Trigger point injections for chronic non-malignant musculoskeletal pain: a systematic review","volume":"10","author":"Scott","year":"2009","journal-title":"Pain Med."},{"key":"10.1016\/j.toxcx.2021.100083_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0128633","article-title":"Neuronox versus BOTOX in the treatment of post-stroke upper limb spasticity: a multicenter randomized controlled trial","volume":"10","author":"Seo","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.toxcx.2021.100083_bib59","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.biopha.2016.09.065","article-title":"Enhancement of orofacial antinociceptive effect of carvacrol, a monoterpene present in oregano and thyme oils, by \u03b2-cyclodextrin inclusion complex in mice","volume":"84","author":"Silva","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.toxcx.2021.100083_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3344\/kjp.2011.24.1.1","article-title":"Application of botulinum toxin in pain management","volume":"24","author":"Sim","year":"2011","journal-title":"Korean J. Pain"},{"key":"10.1016\/j.toxcx.2021.100083_bib61","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0278-2391(03)00153-8","article-title":"Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity","volume":"61","author":"Von Lindern","year":"2003","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.toxcx.2021.100083_bib62","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1016\/j.bbapap.2013.09.007","article-title":"Comparison of the catalytic properties of the botulinum neurotoxin subtypes A1 and A5","volume":"1834","author":"Wang","year":"2013","journal-title":"Biochim. Biophys. Acta Protein Proteonomics"},{"key":"10.1016\/j.toxcx.2021.100083_bib63","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1128\/IAI.00536-13","article-title":"Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro","volume":"81","author":"Whitemarsh","year":"2013","journal-title":"Infect. Immun."}],"container-title":["Toxicon: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590171021000199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590171021000199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:12:20Z","timestamp":1762917140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590171021000199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":63,"alternative-id":["S2590171021000199"],"URL":"https:\/\/doi.org\/10.1016\/j.toxcx.2021.100083","relation":{},"ISSN":["2590-1710"],"issn-type":[{"value":"2590-1710","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analgesic potential of different available commercial brands of botulinum neurotoxin-A in formalin-induced orofacial pain in mice","name":"articletitle","label":"Article Title"},{"value":"Toxicon: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxcx.2021.100083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100083"}}